Patient-Derived Xenograft/PDX Model Market worth $299 million by 2026 - Leading Key Players are JSR Corporation (Japan), WuXi AppTec (China), Champions Oncology, Inc. (US)

According to the new market research report "Patient-Derived Xenograft/PDX Model Market by Type (Mouse, Rat), Tumor Type (Gastrointestinal, Gynecological, Hematological), Application (Preclinical Drug Development, Biomarker analysis), End User (Pharma, Biotech, CROs) - Global Forecast to 2026", published by MarketsandMarkets™, the global Patient-Derived Xenograft Market size is projected to reach USD 299 million by 2026 from USD 140 million in 2021, at a CAGR of 16.4% during the forecast period.

Browse in-depth TOC on "Patient-Derived Xenograft/PDX Model Market"

126 – Tables
34 – Figures
287 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121598251&utm_source=openpr&utm_medium=paidpr

The Market growth is driven mainly by factors such as growing demand for personalized medicine, continuous support for cancer research, and growth in pharma R&D. Rising demand for humanized PDX models is expected to provide growth opportunity for players in the PDX models market. However, the high cost of personalized PDX models, stringent guidelines regarding the ethical use of animals in cancer research, and limitations associated with PDX models are expected to restrain the growth of this market to a certain extent during the forecast period.

The mice models segment accounted for the largest share of the type segment in the PDX models market in 2020.

On the basis of type, the PDX model market is broadly segmented into mice models and rat models. In 2020, mice models accounted for the largest share of the Patient-Derived Xenograft Market. This can primarily be attributed to factors such as ease of procurement, ease of manipulation, and the minimum facility requirement for keeping mice models under observation compared to rats is driving their use in the generation of PDX models.

The preclinical drug development segment accounted for the largest share of the application segment in the PDX models market in 2020.

Based on application, the Patient-Derived Xenograft Market is categorized into three segments—preclinical drug development, biomarker analysis, and basic cancer research. The preclinical drug development application segment accounted for the largest share of the market in 2020. The key factor driving this segments growth is the rising number of clinical trials every year.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=121598251&utm_source=openpr&utm_medium=paidpr

The Asia Pacific region is the fastest-growing region of the PDX models market in2020.

In 2020, Asia Pacific region accounted for the fastest-growing region of the Patient-Derived Xenograft Market. It is also estimated to grow at the highest CAGR in the PDX model market during the forecast period, this is mainly due to factors such as increasing pharmaceutical R&D spending, the growing trend of outsourcing drug discovery services, growing life sciences research, and increasing government initiatives for healthcare research.

Some of the prominent players in the PDX models market are JSR Corporation (Japan), WuXi AppTec (China), Champions Oncology, Inc. (US), The Jackson Laboratory (US), Oncodesign (France), Charles River Laboratories (US), Hera Biolabs (US), EPO Berlin-Buch (Germany), Envigo (US), Xentech (France), Urosphere (France), and Explora BioLabs (US).

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=121598251&utm_source=openpr&utm_medium=paidpr

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

This release was published on openPR.